J
Jeffrey Bennett
Researcher at Anschutz Medical Campus
Publications - 581
Citations - 25101
Jeffrey Bennett is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Choice modelling & Neuromyelitis optica. The author has an hindex of 76, co-authored 544 publications receiving 21098 citations. Previous affiliations of Jeffrey Bennett include Centre for Development Studies & Boston Children's Hospital.
Papers
More filters
Journal Article
Yea-Saying in Contingent Valuation Surveys
TL;DR: In this paper, a new elicitation format, referred to as the dissonance-minimizing (D M) format, is proposed to reduce the occurrence of yea-saying.
Journal ArticleDOI
Choice Modeling and Tests of Benefit Transfer
Mark Morrison,Jeffrey Bennett,Jeffrey Bennett,Russell K. Blamey,Russell K. Blamey,Jordan J. Louviere +5 more
TL;DR: In this paper, the results from three separate choice modeling applications are presented, and the suitability of using stated preference derived estimates for benefit transfer, both across different populations and across different wetlands, are evaluated.
Journal ArticleDOI
Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.
John J. Chen,Eoin P. Flanagan,Jiraporn Jitprapaikulsan,Alfonso Sebastian Lopez-Chiriboga,James P. Fryer,Jacqueline A. Leavitt,Brian G. Weinshenker,Andrew McKeon,Jan Mendelt Tillema,Vanda A. Lennon,W. Oliver Tobin,B. Mark Keegan,Claudia F. Lucchinetti,Orhun H. Kantarci,Collin M. McClelland,Michael S. Lee,Jeffrey Bennett,Victoria S. Pelak,Yanjun Chen,Gregory Vanstavern,Ore-Ofe O Adesina,Eric R. Eggenberger,Marie D. Acierno,Dean M. Wingerchuk,Paul W. Brazis,Jessica Sagen,Sean J. Pittock +26 more
TL;DR: In this paper, the clinical phenotype of myelin oligodendrocyte glycoprotein antibody (MOG-IgG) optic neuritis was characterized using an observational case series.
Journal ArticleDOI
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Anthony Traboulsee,Benjamin Greenberg,Jeffrey Bennett,Lech Szczechowski,Edward Fox,Svitlana Shkrobot,Takashi Yamamura,Y Terada,Yuichi Kawata,Padraig Wright,Athos Gianella-Borradori,Hideki Garren,Brian G. Weinshenker +12 more
TL;DR: Satralizumab monotherapy reduced the rate of NMOSD relapse compared with placebo in the overall trial population, with a favourable safety profile.
Journal ArticleDOI
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
Lukmanee Tradtrantip,Hua Zhang,Samira Saadoun,Puay-Wah Phuan,Chiwah Lam,Marios C. Papadopoulos,Jeffrey Bennett,Alan S. Verkman +7 more
TL;DR: The objective of this study was to develop a potential new NMO therapy based on blocking of pathogenic NMO‐IgG binding to its target, AQP4.